Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form

Selection and evolution of high-affinity human anti-viral antibodies

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Barbas III, Carlos
  • Burton, Dennis

publication date

  • July 1996

journal

  • Trends in Biotechnology  Journal

abstract

  • High-affinity human anti-viral antibodies [e.g. for human immunodeficiency virus type 1 (HIV-1), respiratory syncytial virus (RSV) and herpes simplex virus (HSV)] can be selected from immune phage-display libraries using a variety of strategies. A small subset of these antibodies show potent neutralization in vitro and anti-viral efficacy in vivo in animal models. The affinities of such antibodies arising from secondary or higher order immune responses can be improved using "CDR walking'. Sequential and parallel optimization variants of this strategy have been used to improve the affinity of a prototype anti-HIV-1 antibody 420-fold. Ultra-high-affinity human antibodies could constitute a new class of useful anti-viral reagents.

subject areas

  • Animals
  • Antibodies, Viral
  • Antibody Affinity
  • Binding Sites, Antibody
  • Biotechnology
  • Evolution, Molecular
  • HIV Antibodies
  • HIV-1
  • Humans
  • Immunoglobulin Variable Region
  • In Vitro Techniques
  • Models, Molecular
  • Neutralization Tests
scroll to property group menus

Identity

International Standard Serial Number (ISSN)

  • 0167-7799

Digital Object Identifier (DOI)

  • 10.1016/0167-7799(96)10029-9

PubMed ID

  • 8771795
scroll to property group menus

Additional Document Info

start page

  • 230

end page

  • 234

volume

  • 14

issue

  • 7

©2021 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support